ValiRx plc Total Liabilities
ValiRx plc total liabilities. Based on the latest financial reports, ValiRx plc (VAL) has total liabilities worth £87.45K GBP (≈ $117.43K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ValiRx plc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ValiRx plc (2001–2024)
Total liabilities of ValiRx plc from 2001 to 2024. This chart illustrates how ValiRx plc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of ValiRx plc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
ValiRx plc Competitors by Total Liabilities
The table below lists competitors of ValiRx plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Glacier Lake Resources Inc
V:GLI
|
Canada | CA$1.68 Million |
|
Fuller Smith & Turner
LSE:FSTA
|
UK | GBX292.50 Million |
|
Devernois SA
PA:ALDEV
|
France | €18.33 Million |
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
USA | $4.08 Million |
|
Zonetail Inc
V:ZONE
|
Canada | CA$1.51 Million |
|
Commander Resources Ltd
V:CMD
|
Canada | CA$115.83K |
|
Rincon Resources Ltd
AU:RCR
|
Australia | AU$24.60K |
|
Kmc Properties ASA
OL:KMCP
|
Norway | Nkr10.54 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down ValiRx plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ValiRx plc asset portfolio.
Liquidity & Leverage Metrics
ValiRx plc Total Liabilities Ratios Explained
ValiRx plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ValiRx plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ValiRx plc (2001–2024)
The table below shows the annual total liabilities of ValiRx plc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | £346.41K ≈ $465.20K |
+52.93% |
| 2023-12-31 | £226.51K ≈ $304.18K |
+51.37% |
| 2022-12-31 | £149.65K ≈ $200.96K |
+36.59% |
| 2021-12-31 | £109.56K ≈ $147.12K |
-39.94% |
| 2020-12-31 | £182.40K ≈ $244.95K |
-86.80% |
| 2019-12-31 | £1.38 Million ≈ $1.86 Million |
+14.77% |
| 2018-12-31 | £1.20 Million ≈ $1.62 Million |
-32.54% |
| 2017-12-31 | £1.78 Million ≈ $2.40 Million |
-31.17% |
| 2016-12-31 | £2.59 Million ≈ $3.48 Million |
+340.51% |
| 2015-12-31 | £588.55K ≈ $790.37K |
-29.52% |
| 2014-12-31 | £835.08K ≈ $1.12 Million |
-4.68% |
| 2013-12-31 | £876.10K ≈ $1.18 Million |
+234.86% |
| 2012-12-31 | £261.63K ≈ $351.35K |
+85.56% |
| 2011-12-31 | £141.00K ≈ $189.35K |
-71.97% |
| 2010-12-31 | £503.00K ≈ $675.48K |
-33.64% |
| 2009-12-31 | £758.00K ≈ $1.02 Million |
+85.33% |
| 2008-12-31 | £409.00K ≈ $549.25K |
+321.65% |
| 2007-12-31 | £97.00K ≈ $130.26K |
-7.62% |
| 2006-12-31 | £105.00K ≈ $141.01K |
+1066.67% |
| 2006-03-31 | £9.00K ≈ $12.09K |
-95.61% |
| 2005-12-31 | £205.00K ≈ $275.30K |
+127.78% |
| 2004-12-31 | £90.00K ≈ $120.86K |
+52.54% |
| 2003-12-31 | £59.00K ≈ $79.23K |
-82.80% |
| 2002-12-31 | £343.00K ≈ $460.62K |
-43.68% |
| 2001-12-31 | £609.00K ≈ $817.83K |
-- |
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more